| Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, ... New England Journal of Medicine 377 (26), 2531-2544, 2017 | 5123 | 2017 |
| Review of 1027 patients with newly diagnosed multiple myeloma RA Kyle, MA Gertz, TE Witzig, JA Lust, MQ Lacy, A Dispenzieri, ... Mayo clinic proceedings 78 (1), 21-33, 2003 | 3336 | 2003 |
| Effective surgical adjuvant therapy for high-risk rectal carcinoma JE Krook, CG Moertel, LL Gunderson, HS Wieand, RT Collins, RW Beart, ... New England Journal of Medicine 324 (11), 709-715, 1991 | 2379 | 1991 |
| Targeting apoptosis pathways in cancer therapy IM Ghobrial, TE Witzig, AA Adjei CA: a cancer journal for clinicians 55 (3), 178-194, 2005 | 1880 | 2005 |
| Randomized controlled trial of yttrium-90–labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade … TE Witzig, LI Gordon, F Cabanillas, MS Czuczman, C Emmanouilides, ... Journal of clinical oncology 20 (10), 2453-2463, 2002 | 1596 | 2002 |
| POEMS syndrome: definitions and long-term outcome: Presented in abstract form at the 41st annual meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999. A Dispenzieri, RA Kyle, MQ Lacy, SV Rajkumar, TM Therneau, DR Larson, ... Blood, The Journal of the American Society of Hematology 101 (7), 2496-2506, 2003 | 1232 | 2003 |
| International consensus guidance statement on the management and treatment of IgG4‐related disease A Khosroshahi, ZS Wallace, JL Crowe, T Akamizu, A Azumi, ... Arthritis & rheumatology 67 (7), 1688-1699, 2015 | 1140 | 2015 |
| Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis A Dispenzieri, MA Gertz, RA Kyle, MQ Lacy, MF Burritt, TM Therneau, ... Journal of clinical oncology 22 (18), 3751-3757, 2004 | 1055 | 2004 |
| A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine RA Kyle, MA Gertz, PR Greipp, TE Witzig, JA Lust, MQ Lacy, TM Therneau New England Journal of Medicine 336 (17), 1202-1207, 1997 | 896 | 1997 |
| Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma TE Witzig, IW Flinn, LI Gordon, C Emmanouilides, MS Czuczman, ... Journal of clinical oncology 20 (15), 3262-3269, 2002 | 893 | 2002 |
| Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma SV Rajkumar, SR Hayman, MQ Lacy, A Dispenzieri, SM Geyer, B Kabat, ... Blood 106 (13), 4050-4053, 2005 | 878 | 2005 |
| Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+ B-Cell Non-Hodgkin's Lymphoma TE Witzig, CA White, GA Wiseman, LI Gordon, C Emmanouilides, ... Journal of clinical oncology 17 (12), 3793-3803, 1999 | 737 | 1999 |
| Rituximab for IgG4-related disease: a prospective, open-label trial MN Carruthers, MD Topazian, A Khosroshahi, TE Witzig, ZS Wallace, ... Annals of the rheumatic diseases 74 (6), 1171-1177, 2015 | 725 | 2015 |
| Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013 JR Mikhael, D Dingli, V Roy, CB Reeder, FK Buadi, SR Hayman, ... Mayo Clinic Proceedings 88 (4), 360-376, 2013 | 699 | 2013 |
| Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma SV Rajkumar, S Hayman, MA Gertz, A Dispenzieri, MQ Lacy, PR Greipp, ... Journal of Clinical Oncology 20 (21), 4319-4323, 2002 | 687 | 2002 |
| Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma TE Witzig, SM Geyer, I Ghobrial, DJ Inwards, R Fonseca, P Kurtin, ... Journal of Clinical Oncology 23 (23), 5347-5356, 2005 | 632 | 2005 |
| Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma Y Alsayed, H Ngo, J Runnels, X Leleu, UK Singha, CM Pitsillides, ... Blood 109 (7), 2708-2717, 2007 | 582 | 2007 |
| Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma ZZ Yang, AJ Novak, MJ Stenson, TE Witzig, SM Ansell Blood 107 (9), 3639-3646, 2006 | 560 | 2006 |
| Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience PA Hart, MD Topazian, TE Witzig, JE Clain, FC Gleeson, RR Klebig, ... Gut 62 (11), 1607-1615, 2013 | 496 | 2013 |
| An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma TE Witzig, JM Vose, PL Zinzani, CB Reeder, R Buckstein, JA Polikoff, ... Annals of Oncology 22 (7), 1622-1627, 2011 | 489 | 2011 |